NCT00274963已完成2 期
Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 24
- 主要终点
- Overall remission rate (partial and complete remission)
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as bendamustine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bendamustine together with mitoxantrone works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
详细描述
OBJECTIVES:
Primary
- Determine the response rate (remission rate) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) treated with bendamustine and mitoxantrone hydrochloride.
Secondary
- Determine the progression-free survival and overall survival of patients treated with this regimen.
- Determine the safety and tolerability of this regimen in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Overall remission rate (partial and complete remission)
次要结局
- Time to progression
- Safety and tolerability
- Overall survival
研究者
研究点 (24)
Loading locations...
相似试验
已完成
2 期
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaLymphomaLeukemiaNCT00669318Mayo Clinic41
撤回
2 期
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00758693University of Kentucky
终止
3 期
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic LymphomaLymphomaNCT00275106Children's Cancer and Leukaemia Group600
已完成
2 期
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung CancerLung CancerNCT00984542Vanderbilt-Ingram Cancer Center50
已完成
2 期
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerFallopian Tube CancerPeritoneal Cavity CancerOvarian CancerNCT00217555Fred Hutchinson Cancer Center